ObjectiveTo investigate the clinical effect of Dahuang Zhechong capsules combined with entecavir in the treatment of chronic hepatitis B (CHB) patients with liver fibrosis. MethodsA total of 100 CHB patients with liver fibrosis who visited or were hospitalized in Shenzhen Hospital of Peking University from October 2014 to January 2016 were enrolled and randomly divided into Western medicine group and combined treatment group, with 50 patients in each group. The patients in the Western medicine group were given entecavir, and those in the combined treatment group were given Dahuang Zhechong capsules in addition to entecavir. The course of the treatment was 48 weeks. The changes in liver function, HBV DNA load, four serum parameters of liver fibrosis, liver stiffness, and aspartate aminotransferase-to-platelet ratio index (APRI)/FibroIndex were observed in both groups. The t-test was used for comparison of continuous data between groups, and the chi-square test was used for comparison of categorical data between groups. ResultsBoth groups showed significant reductions in serum levels of aspartate aminotransferase (AST), alanine aminotransferase (ALT), and HBV DNA load after 48 weeks of treatment (all P＜0.05). After treatment, the four serum parameters of liver fibrosis all returned to normal after treatment, and the serum levels of hyaluronic acid, type Ⅲ precollagen, and type IV collagen showed significant differences between the two groups (all P＜005), and the portal vein diameter, thickness of the spleen, liver stiffness and APRI/FibroIndex also showed significant differences between the two groups (both P＜0.05). The combined treatment group had a significantly higher overall response rate than the Western medicine group (920% vs 720%, χ2=6.775, P=0009). ConclusionDahuang Zhechong capsules combined with entecavir have a better effect in the treatment of CHB patients with liver fibrosis compared with entecavir alone.

OBJECTIVE:To provide reference for rational drug use and strengthen the management of adjuvant medication man-agement in the hospital. METHODS:1 080 and 860 discharged medical records of 12 Vitamins for injection were selected from our hospital during Jun.-Nov. 2014 (pre-special comment group,i.e. group A) and Jun.-Nov. 2015 (post-special comment group,i.e. group B),respectively. The application of 12 Vitamins for injection,hospitalization stay,drug cost and the incidence of ADR were compared before and after adjuvant medication special comment. RESULTS:After adjuvant medication special comments,the propor-tion of drug use of no indication,unsuitable solvent selection,irrational drug dosage,drug use of drug interaction and contraindica-tion,drug cost and the incidence of ADR in group B were all lower than in group A,with statistical significance(P<0.05). There was no statistical significance in hospitalization stay between 2 groups(P>0.05). CONCLUSIONS:Clinical pharmacists adopt adju-vant medication special comments to effectively standardize clinical application of 12 Vitamins for injection in our hospital.

【Objective】 To study the screening and confirmatory test of human T-lymphotropic virus(HTLV) in blood donors. 【Methods】 Anti HTLV-1 / 2 screening was conducted on voluntary blood donors from 9 cities in Fujian province betweenJan. 12016toDec. 312018.Plasma samples ofanti-HTLV-1/2 reactive donors werecollected and sent to Xiamen Blood Center for confirmatory test. The influence of different screening reagents and confirmatory test methods on the test results were analyzed. 【Results】 A total of 741 anti-HTLV-1/2 reactivesamples were collected, among which 252 were positiveby Western Blot, 15undetermined, and 474negative, withthe overall positive rate at 34.0% (252/741). The yielding rate of domestic reagent A was significantly differentbyregions, withthe highest in Ningde(73.9%, 88/119) and the lowest in Zhangzhou(4.0%, 4/99). The confirmedpositive rates of anti-HTLV-1/2 screening reagent A(domestic) and B(imported)were 33.3%(13/39) and 57.1%(56/98), respectively, and the difference was statistically significant(P<0.01). When S / CO >5, the reagent Ayielding rate was 76.5%(13/17), significantly lower than that of imported reagent Bas 100%(56/56) (P<0.01). A total of 652 anti-HTLV-1 / 2 reactive samples were confirmed by Western Blot and nucleic acid test in parallel, among which 638 results were concordant, 14 were not, with the overall concordance rate at 97.85%. 【Conclusion】 Comparable differences in the yielding rate of twoanti-HTLV screening reagents were observed.There was over allhighconcordance, but also complementarity, between Western Blot and nucleic acid test.